News

Impilo believes in transparency. We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Accordingly, we present information about our operations and our investments in order to increase transparency. 

 If you would like to receive a notification via e-mail when we publish a news update please submit your e-mail adress below. 

I have read and accepted the Impilo privacy policy

20 Jan 2021

Impilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract Research Organization

Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been acquired by the leading Nordic healthcare investment company, Impilo, together with the management team of Scantox. The Company is formerly known as Charles River Copenhagen A/S and will today be renamed to Scantox A/S and continue its business operations as a fully independent company.

4 Jan 2021

Immedica and WinHealth enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area , South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. The pharmaceutical drug product Ravicti® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is granted a license to register and commercialize the product in UCD in the countries of the specified territory.

15 Dec 2020

Impilo and Anders Larnholt form a partnership to create a new pan‐European pharmaceutical platform

Impilo is pleased to have partnered with Anders Larnholt, an experienced pharma and healthcare executive, to create a new platform; Mallax Pharmaceuticals AB (“Mallax”). Mallax was founded in Sweden, with the aim of building a company with established pharmaceuticals and OTC products for customers and patients across Europe.

6 Nov 2020

Immedica acquires the rights for Ravicti® and Buphenyl® for Japan from Horizon Therapeutics plc.

Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated for the treatment of Urea Cycle Disorders (UCD), in Japan from Horizon Therapeutics plc (Nasdaq: HZNP) (Horizon).

29 Apr 2020

PharmaMar signs an agreement with Immedica

PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries

19 Nov 2019

The Swedish Financial Supervisory Authority has approved the consortium of investors arranged by Impilo as new owners of Euro Accident Livförsäkring

01 Oct 2019

Immedica acquires the rights for Ophthalmology products for European countries

Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories.

17 Sep 2019

Impilo launches collaboration with Kenyan non-profit innovators

The Nordic investment company Impilo partners with Lwala Community Alliance in Kenya to reduce maternal and child mortality in rural areas. Impilo will provide both financial and strategic support to scale their innovative community-based model.

03 Sep 2019

A consortium of investors arranged by Impilo has entered an agreement to acquire Euro Accident Livförsäkring from National General Holdings Corp.

Euro Accident is a leading Swedish specialist in health-related insurance and employee wellbeing, active primarily within the long-term disability, pension risk and private health insurance. Impilo together with management and a group of other investors have agreed to acquire Euro Accident from the current owners National General Holdings Corp., a specialty personal lines insurance company listed on NASDAQ (NGHC).

11 Jul 2019

The Fertility Partnership acquires VivaNeo to create Northern Europe’s leading Fertility Group

The Fertility Partnership has today signed an agreement to acquire VivaNeo GmbH from Waterland Private Equity. VivaNeo is one of the leading European providers of fertility services with 9 clinics supported by 5 satellite clinics across Germany, Austria, Denmark and the Netherlands. The group includes a blood diagnostics laboratory in Germany servicing the local market and some international clinics, as well as a dialysis business in Germany.

Se flere nyheder

Media

We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Here you will find press information, news and media material.

Go to Cision

Redefining know-how

Impilo is zulu and xhosa meaning life, health or simply the meaning of a healthy life. We chose this name to highlight our sector-focus and our ambition to provide know-how and new perspectives to Nordic healthcare companies.